Zobrazeno 1 - 10
of 82
pro vyhledávání: '"E.D. Kreuser"'
Autor:
Silvia Sander, K. H. Link, Ludger Staib, W. Baumann, Andrea Formentini, Marko Kornmann, Martina Kron, E.D. Kreuser, Doris Henne-Bruns, C. Ette
Publikováno v:
European Journal of Surgical Oncology (EJSO). 34:1316-1321
Adjuvant chemotherapy is recommended for stage III colon cancer. The aim of this study was to identify important prognostic factors among patients with colon cancer receiving adjuvant 5-FU-based treatment.Data sets of 855 colon cancer patients treate
Autor:
G Hartung, J Kühnel, Wolfgang Queisser, A. Wein, A. Rost, Ruediger Hehlmann, D. Fritze, R.D. Hofheinz, E.D. Kreuser, M Drees, C. Riedel
Publikováno v:
Oncology Research and Treatment. 24:457-462
A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium - folinic acid (S-FA) is a new formulation w
Autor:
Ludger Staib, E. Röttinger, P. Suhr, K. H. Link, Hans-Günther Beger, E.D. Kreuser, H. Bernhart
Publikováno v:
Oncology Research and Treatment. 20:235-238
Purpose: FOGT has initiated two prospective controlled randomized trials to improve adjuvant therapy of colon cancer stages UICC II / T4N0M0 and III (FOGT1) and rectal cancer st
Autor:
M. Streit, U. Harms, U. Mansmann, J. Schulz, Eckhard Thiel, M. Koenigsmann, E.D. Kreuser, Wolfgang E. Berdel
Publikováno v:
Oncology Research and Treatment. 17:528-537
Background : Cell adhesion to extracellular matrix (ECM) components can be analyzed by quantifying the fraction of adherent cells. Various indirect methods for cell counting are bein
Autor:
J. Reichert, T. Zwingers, R.U. Hilgenfeld, D. Zillig, H.W. Dreyer, R. Pasold, Karsten Ridwelski, P.M. Ehrich, T. Küchler, Stefan Schwartz, W. Abenhardt, E.D. Kreuser, J.B. Boese-L·andgraf, M. Kairies, L. Reichel, P. David, Ch. Boewer, W. Stein, S.K. Jakob, Wolfgang E. Berdel, Eckhard Thiel, F. Bach, M. Matthias, R. Böthig
Publikováno v:
Oncology Research and Treatment. 17:78-84
Background : The biochemical rationale for the use of folinic acid (FA) and interferon (IFN) to modulate and thereby enhance the antitumor activity of 5-fluorouracil (5-FU) in vitro
Autor:
Shigehiko Mizutani, G. Kouvatseas, Junji Yamamoto, Z. Zoumbos, Ryoko Iwata, Masayoshi Yoshimori, E. Thiel, Alfred Rademaker, P. Hohenberger, N. Haboubi, Tetsuo Imamura, Massimo Mannelli, Tadeusz Dobosz, Gerald A. Soff, Jiangou Liu, Satoshi Abe, Setsuo Hirohashi, Nikolaus Blin, Hiroshi Nakazato, Jen-Der Lin, Noriyuki Moriyama, D. Pectasides, Yoshitake Takagi, Jiro Fujimoto, Anne-Paule Gimenez-Roqueplo, Anna Kuczyńska, H Furukawa, Tomoo Kosuge, Reiko Hirose, Yoshiomi Mori, Nicolas Charlet-Berguerand, C. Nikolaides, Suzanne French, M.A. Dimopoulos, Ewa Jankowska, Ch. Kiamouris, D. Skarlos, Mayumi Sekiguchi, Tohgo Ohno, E.D. Kreuser, Jui-Hung Sun, Noel P. Bouck, Maria Sąsiadek, Cheng Ho, N. Pavlidis, Hervé Le Hir, Pierre-François Plouin, Al B. Benson, Hiroshi Miki, A. Antoniou, T. Economopoulos, Michiie Sakamoto, Claude Thermes, Hsiao-Fen Weng, Teruhiko Tamaya, C. Tsatalas, Tetsuro Nagasaka, Susumu Yamasaki, William J. Gradishar, Hideki Ueno, Vittorio de Franciscis, Masafumi Ikeda, Shuichi Okada, Tzu-Chieh Chao, Takuji Okusaka, Fumitaka Kikkawa, W.E. Berdel, H. Lochs, Kazunori Hoshimoto, Kazutoshi Unno, E. Pappa, Hidehiko Fujimura, H. Szelényi, Takashi Matsushita, Kazuaki Shimada, Masatoshi Hayashi, Akio Tateishi, Hirotaka Nakano, Yoshiharu Katoh, Angela Cisneros, G. Fountzilas, Kazuhiko Ino, Toshiko Moue, Tadeusz Łukienczuk, Hideki Sakaguchi, Nobuo Nakashima, Takeyoshi Ohkura, G. Aravantinos, Tatsuo Itoh, A. Halikia
Publikováno v:
Oncology. 58:357-359
Autor:
H. Ludwig, K. Havemann, K. Pollow, B. Kornhuber, G. Maschmeyer, M.E. Heim, H. Deicher, W. Hiddemann, H. Wilke, L. Hoffmann, F. Overkamp, K. Lennert, R. Waldmann, M.v. Bülow, H. Gisslinger, H. Köppler, W. Bätz, H. Stein, A. Grothey, E. Fritz, U. Cammerer, M. Fritz, H. Flechtner, J. Stirbu, S. Kunz, D.K. Hossfeld, L. Edler, G.v. Ingersleben, D. Schmähl, C. Gropp, S. Verhees, W. Queißer, M.R. Berger, E. Busse, R. Herrmann, J. Selbach, P. Drings, S. Oehl, H. Konyar, U. Bruntsch, D. Hossfeld, I.-M. v. Broen, R. Holle, V. Cour, H. Link, D. Adam, F. Trux, A. Sinop, H. Kuhn, W. Zeller, E.U. Steinhauer, E. Neeser, B. Steinke, P. Unterburger, K. Schumacher, J.P. Obrecht, B. Mentges, P. Preusser, H. Langenbahn, R. Coldewey, M. Fink, A. Ganser, E. Lötzke, J. Hartlapp, R. Pfab, K. Höffken, M. Flasshove, M. Helmerking, H. J. Schmoll, D. Peest, W. Noder, H. Kotzmann, D. Hoelzer, H.O. Klein, E.D. Kreuser, H.H. Goßmann, H.J. Weh, H.-J. Grill, H. Ehrhart, R. Hein, K.H. Pflüger, C.N. Gutt, E. Heidemann, I. Eschenbach, K. Possinger, P. Meyer
Publikováno v:
Oncology Research and Treatment. 13:57-60
Autor:
E.D. Kreuser, Link H, Pichlmeier U, J. Kuhfahl, Wagner H, D. Fritze, Schulte F, Steinbrecher C, Wagner T
Publikováno v:
Onkologie. 27(5)
Background: A weekly continuous 24-h infusion therapy with 5-fluorouracil (5-FU) preceded by a 2-h infusion of calcium folinate (CA-FA) was shown to be an effective first- and second-line treatment in advanced metastatic colorectal cancer. Substituti
Publikováno v:
International journal of immunopharmacology. 19(6)
Recent animal studies demonstrate that prothymosin alpha 1 (ProT alpha) enhances the antitumor response by stimulation of mononuclear phagocyte functions. The present study was aimed at characterizing the in vitro effects by ProT alpha on blood monoc
Publikováno v:
New Perspectives in Molecular and Clinical Management of Gastrointestinal Tumors ISBN: 9783642800375
Colon cancer patients with UICC stage III or T4 N0 M0 stage II should receive postoperative adjuvant therapy, since relapse rates are high and surgical outcome has been improved by adjuvant treatment. The standard treatment is 5-fluourouracil plus le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3be32d5214278cfd05b8268a1f22a8fd
https://doi.org/10.1007/978-3-642-80035-1_19
https://doi.org/10.1007/978-3-642-80035-1_19